Patients
HER2-positive tumors
DISEASE, RECURRENCE, RECURRENT DISEASE
Eligible patients were aged ≥ 18 years (≥ 20 years in Japan); had an ECOG PS of 0–1; had histologically confirmed, non-resectable, mGC/GEJC; and had previously received ≥ 2 standard-of-care regimens for advanced disease.Previous regimens must have included a fluoropyrimidine; a platinum agent; and a taxane, IRI, or both. Patients with HER2-positive tumors must have received prior anti-HER2 therapy, if available. Adjuvant therapy could be regarded as one previous regimen in patients who had recurrence during or within 6 months of postoperative adjuvant completion. In cases of preoperative and postoperative adjuvant chemotherapy, adjuvant therapy could be regarded as one previous regimen only if the same regimen was administered both preoperatively and postoperatively. Patients with recurrent disease were eligible providing that they had received ≥ 2 lines of chemotherapy.